Cargando…
Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
BACKGROUND: Aberrant MET tyrosine kinase signaling is known to cause cancer initiation and progression. While MET inhibitors are in clinical trials against several cancer types, the clinical efficacies are controversial and the molecular mechanisms toward sensitivity remain elusive. METHODS: With th...
Autores principales: | Kou, Jianqun, Musich, Phillip R., Staal, Ben, Kang, Liang, Qin, Yuan, Yao, Zhi Q., Zhang, Boheng, Wu, Weizhong, Tam, Angela, Huang, Alan, Hao, Huai-Xiang, Vande Woude, George F., Xie, Qian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134500/ https://www.ncbi.nlm.nih.gov/pubmed/30208970 http://dx.doi.org/10.1186/s12967-018-1628-y |
Ejemplares similares
-
Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
por: Qin, Anna, et al.
Publicado: (2023) -
Characterizing the roles of Met31 and Met32 in coordinating Met4-activated transcription in the absence of Met30
por: Carrillo, Emilio, et al.
Publicado: (2012) -
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
por: Kentsis, Alex, et al.
Publicado: (2012) -
Overexpression of HGF/MET axis along with p53 inhibition induces de novo glioma formation in mice
por: Qin, Yuan, et al.
Publicado: (2020) -
Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma
Progression and Is an Effective Indicator for Met-Targeting Therapy
por: Xie, Qian, et al.
Publicado: (2013)